Dr. Qianqian Wang, MD, FRCSC

Claim this profile

Centre Hospitalier de l'Université de Montréal

Studies Glaucoma
Studies Corneal Disorder
2 reported clinical trials
3 drugs studied

Affiliated Hospitals

Image of trial facility.
Centre Hospitalier De L'Université De Montréal
Image of trial facility.
Centre Hospitalier De L'Université De Montréal (CHUM)

Clinical Trials Qianqian Wang, MD, FRCSC is currently running

Image of trial facility.

Laser Treatment

for Glaucoma Prevention in Corneal Disease

The Boston keratoprosthesis (KPro) is a special plastic device that is used to replace a sick cornea (transparent part of the eye, in front of the iris) in order to restore vision in patients who have failed traditional corneal transplants or have a very poor prognosis of success. Glaucoma is a chronic disease which causes optic nerve damage secondary to high pressure inside the eye and could lead to vision loss in the long term. Glaucoma is highly prevalent in patients who require a KPro and even more after their procedure. In order to decrease the intra-ocular pressure, surgeons can use multiple eyedrops. Unfortunately, following the KPro surgery, eyedrops lose their efficiency because they are less absorbed by the eye. The transscleral cyclophotocoagulation (TS-CPC) is a laser treatment used in advanced refractory glaucoma. This laser helps decrease the intra-ocular pressure and have a better control of the disease. There are different methods of laser transmission, including the continuous transmission (G-Probe) and the micro-pulsation method (Micopulse). Given the high prevalence of glaucoma in patients receiving a KPro, the investigators are studying the effect of giving the TS-CPC treatment prophylactically to patients before their Boston keratoprosthesis. Our hypothesis is that prophylactic TS-CPC will decrease glaucoma progression as well as the risks of developing glaucoma following the Boston keratoprosthesis . METHOD The investigators aim to recruit twenty (20) patients who are scheduled to receive Boston KPro. Participants will be randomized into two groups: 1) Groupe 1 will receive a prophylactic treatment of transscleral cyclophotocoagulation a G-Probe. 2) Groupe 2 will receive a prophylactic treatment of transscleral cyclophotocoagulation with a micropulse transmission (MicroPulse). The patients will receive their laser treatment by a glaucoma specialist 4 to 8 weeks before their KPro surgery. One week following their laser treatment, the participants will be examined by their glaucoma specialist. Following their KPro surgery, patients will have a follow-up at day-1, weeks 1 and 2, months 1 and 3, then every 4 to 6 months for 5 years. Additional non-invasive glaucoma tests will be performed twice during the first 3 months following the surgery and will be repeated every 4-6 months. Visual acuity results, the visual field tests and rates of post-operative complications will be compared between the different groups.
Recruiting1 award N/A

More about Qianqian Wang, MD, FRCSC

Clinical Trial Related5 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Qianqian Wang, MD, FRCSC has experience with
  • Topical Insulin Drops
  • G-Probe Transscleral Cyclphophotocoagulation
  • Transscleral Cyclphophotocoagulation Using The Micropulse System

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Qianqian Wang, MD, FRCSC specialize in?
Is Qianqian Wang, MD, FRCSC currently recruiting for clinical trials?
Are there any treatments that Qianqian Wang, MD, FRCSC has studied deeply?
What is the best way to schedule an appointment with Qianqian Wang, MD, FRCSC?
What is the office address of Qianqian Wang, MD, FRCSC?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security